Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography
The purpose of this study was to noninvasively monitor the therapeutic efficacy of cyclophosphamide (CTX) in a mouse model by dual-modality molecular imaging: positron emission tomography (PET) and bioluminescence imaging (BLI). Firefly luciferase (fLuc) transfected HCC-LM3-fLuc human hepatocellular...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-07-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2010.00041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561850648461312 |
|---|---|
| author | Xibo Ma Zhaofei Liu Xin Yang Qiujuan Gao Shouping Zhu Chenghu Qin Kai Liu Bo Zhang Dong Han Fan Wang Jie Tian |
| author_facet | Xibo Ma Zhaofei Liu Xin Yang Qiujuan Gao Shouping Zhu Chenghu Qin Kai Liu Bo Zhang Dong Han Fan Wang Jie Tian |
| author_sort | Xibo Ma |
| collection | DOAJ |
| description | The purpose of this study was to noninvasively monitor the therapeutic efficacy of cyclophosphamide (CTX) in a mouse model by dual-modality molecular imaging: positron emission tomography (PET) and bioluminescence imaging (BLI). Firefly luciferase (fLuc) transfected HCC-LM3-fLuc human hepatocellular carcinoma cells were injected subcutaneously into BALB/c nude mice to establish the experimental tumor model. Two groups of HCC-LM3-fLuc tumor-bearing mice ( n = 7 per group) were treated with saline or CTX (100 mg/kg on days 0, 2, 5, and 7). BLI and 18 F-fluorodeoxyglucose ( 18 F-FDG) PET scans were done to evaluate the treatment efficacy. CTX induced a 25.25 ± 13.13% and 35.91 ± 25.85% tumor growth inhibition rate on days 9 and 12 posttreatment, respectively, as determined by BLI. A good linear correlation was found between the tumor sizes measured by caliper and the BLI signals determined by optical imaging ( R 2 = .9216). 18 F-FDG imaging revealed a significant uptake reduction in the tumors of the CTX-treated group compared to that in the saline control group (5.30 ± 1.97 vs 3.00 ± 2.11% ID/g) on day 16 after CTX treatment. Dual-modality molecular imaging using BLI and small-animal PET can play important roles in the process of chemotherapy and will provide noninvasive and reliable monitoring of the therapeutic response. |
| format | Article |
| id | doaj-art-4f10fb00e5dd42e28637795f6291f52f |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2011-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-4f10fb00e5dd42e28637795f6291f52f2025-01-03T01:23:07ZengSAGE PublishingMolecular Imaging1536-01212011-07-011010.2310/7290.2010.0004110.2310_7290.2010.00041Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission TomographyXibo MaZhaofei LiuXin YangQiujuan GaoShouping ZhuChenghu QinKai LiuBo ZhangDong HanFan WangJie TianThe purpose of this study was to noninvasively monitor the therapeutic efficacy of cyclophosphamide (CTX) in a mouse model by dual-modality molecular imaging: positron emission tomography (PET) and bioluminescence imaging (BLI). Firefly luciferase (fLuc) transfected HCC-LM3-fLuc human hepatocellular carcinoma cells were injected subcutaneously into BALB/c nude mice to establish the experimental tumor model. Two groups of HCC-LM3-fLuc tumor-bearing mice ( n = 7 per group) were treated with saline or CTX (100 mg/kg on days 0, 2, 5, and 7). BLI and 18 F-fluorodeoxyglucose ( 18 F-FDG) PET scans were done to evaluate the treatment efficacy. CTX induced a 25.25 ± 13.13% and 35.91 ± 25.85% tumor growth inhibition rate on days 9 and 12 posttreatment, respectively, as determined by BLI. A good linear correlation was found between the tumor sizes measured by caliper and the BLI signals determined by optical imaging ( R 2 = .9216). 18 F-FDG imaging revealed a significant uptake reduction in the tumors of the CTX-treated group compared to that in the saline control group (5.30 ± 1.97 vs 3.00 ± 2.11% ID/g) on day 16 after CTX treatment. Dual-modality molecular imaging using BLI and small-animal PET can play important roles in the process of chemotherapy and will provide noninvasive and reliable monitoring of the therapeutic response.https://doi.org/10.2310/7290.2010.00041 |
| spellingShingle | Xibo Ma Zhaofei Liu Xin Yang Qiujuan Gao Shouping Zhu Chenghu Qin Kai Liu Bo Zhang Dong Han Fan Wang Jie Tian Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography Molecular Imaging |
| title | Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography |
| title_full | Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography |
| title_fullStr | Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography |
| title_full_unstemmed | Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography |
| title_short | Dual-Modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-Animal Positron Emission Tomography |
| title_sort | dual modality monitoring of tumor response to cyclophosphamide therapy in mice with bioluminescence imaging and small animal positron emission tomography |
| url | https://doi.org/10.2310/7290.2010.00041 |
| work_keys_str_mv | AT xiboma dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT zhaofeiliu dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT xinyang dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT qiujuangao dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT shoupingzhu dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT chenghuqin dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT kailiu dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT bozhang dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT donghan dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT fanwang dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography AT jietian dualmodalitymonitoringoftumorresponsetocyclophosphamidetherapyinmicewithbioluminescenceimagingandsmallanimalpositronemissiontomography |